MyFinsight
Home
Blog
About
Net income (gain)
attributable to common...
-$4,276,377
(-477.31%↓ Y/Y)
Net income (gain)
-$4,274,430
(-481.39%↓ Y/Y)
Net income (loss) at
subsidiary attributable to...
$1,947
(-64.81%↓ Y/Y)
Net loss from
continuing operations
-$3,104,171
Net income (loss)
from discontinued...
-$1,170,259
Product Talicia
$2,349,890
Product Sancuso
$1,816,737
(-41.75%↓ Y/Y)
Product Vibativ
$1,738,887
(-35.64%↓ Y/Y)
Product Caldolor
$1,474,288
(-7.18%↓ Y/Y)
Product Kristalose
$1,061,442
(-61.46%↓ Y/Y)
Product Other
$221,534
(-55.01%↓ Y/Y)
Product Acetadote
$136,661
(-29.39%↓ Y/Y)
Revenues, including
adjustments-Product Redi Trex
$1,802
(-44.45%↓ Y/Y)
Loss before income
taxes
-$3,100,301
(-324.97%↓ Y/Y)
Income tax expense
$3,870
(-31.76%↓ Y/Y)
Interest income
$60,884
(-52.24%↓ Y/Y)
Revenues
$8,801,241
Operating gain
-$3,160,461
(-322.82%↓ Y/Y)
Net revenues from
continuing operations
$166,458
(-98.46%↓ Y/Y)
Interest expense
$724
(-99.34%↓ Y/Y)
Net revenues
-$8,634,783
(-179.68%↓ Y/Y)
Total costs and
expenses
$3,326,919
(-71.28%↓ Y/Y)
General and
administrative
$2,547,606
(-11.39%↓ Y/Y)
Research and development
$772,162
(-47.41%↓ Y/Y)
Amortization
$7,151
(-99.29%↓ Y/Y)
Back
Back
Income Statement
CUMBERLAND PHARMACEUTICALS INC (CPIX)
CUMBERLAND PHARMACEUTICALS INC (CPIX)
source: myfinsight.com